There are 3161 resources available
1095P - Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
Presenter: Alexander Eggermont
Session: Poster session 04
1096P - Camrelizumab plus apatinib in patients with advanced mucosal melanoma: A 3-year survival update with biomarker analysis
Presenter: Zhengyun Zou
Session: Poster session 04
1098P - Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial
Presenter: Ryan Sullivan
Session: Poster session 04
1099P - COMBI-EU: Adverse event management of adjuvant dabrafenib plus trametinib (D+T) in patients with BRAF V600-mutant melanoma
Presenter: Peter Mohr
Session: Poster session 04
1100P - Anti-PD1 + low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysis
Presenter: Igor Samoylenko
Session: Poster session 04
1101P - Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Presenter: Mario Mandalà
Session: Poster session 04
1102P - Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
Presenter: Allison Betof Warner
Session: Poster session 04
1103P - Real-world efficacy of relatlimab and nivolumab in advanced or resectable melanoma
Presenter: Lilit Karapetyan
Session: Poster session 04
1104P - Early time-point <sup>18</sup>F-FDG-PET/CT at week four (W4) as a prognostic biomarker of survival in metastatic melanoma (mM) patients (pts) on immunotherapy
Presenter: Nezka Hribernik
Session: Poster session 04